Overview
Hemas is a diversified group spanning healthcare, consumer brands, mobility, leisure, travel and logistics, with healthcare the largest reported segment. Its portfolio provides exposure to defensive pharmaceutical and hospital activities alongside more cyclical consumer and mobility businesses.
The most important change is the contrast between a strong audited year and a softer latest quarter. The June quarter retained revenue momentum, but cost pressure and weaker operating leverage reduced earnings, making execution across the portfolio more important than headline sales growth.
Price performance
HHL closed at LKR 31.40 on 17 August 2026. The share fell 4.0% over three months and 8.4% over six months, broadly in line with the ASPI's declines of 5.6% and 9.0% over the same periods, but its one-year return of 1.0% lagged the index's 9.6% gain.
The price sits 14.0% below its 52-week high and 12.1% above its low, placing it at 40.0% of its own annual range. Recent trading has been quieter than its own prior norm: 60-day annualised volatility was 16.6%, 26.7% below its one-year measure, while 20-day volume was 35.8% below the 60-day average.
Valuation
HHL's 10.84 times P/E is at the 31st sector percentile, indicating a lower earnings multiple than most diversified-holdings peers. Its 1.69 times P/B is at the 75th percentile, while 15.7% return on equity supports a premium to the sector's 1.16 times median P/B more than a weak balance-sheet argument would.
The 3.2% dividend yield is at the 60th sector percentile. The payout has been rising rather than shrinking, with dividends per share of LKR 0.68 in FY2024, LKR 0.90 in FY2025 and LKR 1.00 in FY2026. The FY2026 payout ratio was 34.5%, with dividend cover of 2.9 times.
News and sentiment
Coverage has been unusually heavy, with 5 articles in the last 30 days versus the company's baseline of 2.5 per month. Across the last 90 days, 12 of 19 material articles were positive, 6 negative and 1 neutral.
The main new development on 17 August was Hemas's acquisition of a 75% stake in Kenya's Twiga Stationers & Printers for $16.2 million, its first international acquisition. The transaction broadens Atlas Axillia's consumer-brand footprint, but the available coverage does not quantify its earnings contribution. A final dividend of LKR 0.75 per share went ex-dividend on 30 June 2026 and was paid on 17 July.
Financials
The June 2026 quarter was materially weaker below the revenue line. Revenue rose 0.9% year-on-year to LKR 28.77 billion, but operating profit fell 21.1% to LKR 1.63 billion and net profit fell 15.7% to LKR 1.06 billion. The LKR 569 million gap between operating and net profit reflects finance costs, tax, associates and foreign-exchange effects rather than operating expansion.
All latest-quarter margins are on a group basis and are comparable with the year-ago group figures. Gross margin widened from 30.1% to 30.4%, but operating margin narrowed from 7.2% to 5.7% and net margin from 4.4% to 3.7%. June is structurally the weakest quarter for operating margin; the latest 5.7% ranked middling at 5th of 7 comparable June quarters, while gross margin ranked among its best at 2nd of 7.
The twelve months to June 2026 produced revenue of LKR 127.61 billion, up 5.4%, with a 10.7% operating margin and 7.1% net margin. Equity attributable to owners was LKR 55.80 billion and shares outstanding were 2.996 billion. The 1:5 share subdivision effective 7 May 2025 mechanically reduced per-share figures, so historical EPS comparisons require the restated share basis.
The 7 August 2026 results coverage is later than the 30 June financial data and reports the same quarter as Q1 FY27: EBITDA of LKR 2.26 billion, down 14.1%, and earnings attributable to equity holders of LKR 937 million, down 21.4%. These reported figures reinforce that the latest print is historical and that the group had already moved into margin-recovery actions by the time of publication.
Risks
The leading risk is weak cash conversion alongside uneven operating earnings. For the twelve months to June 2026, operating cash conversion was negative 0.4 times, meaning reported operating profit did not arrive as operating cash over that window. At March 2026, annual cash conversion was stronger at 0.83 times but still below one.
Financial leverage is modest but not irrelevant: gearing was 10.8% of owners' equity, interest cover was 13.79 times and the current ratio was 1.72. These measures provide protection, although a prolonged margin squeeze would reduce interest-cover headroom.
Healthcare represents 62.4% of reported segment revenue, so pharmaceutical supply, regulatory and hospital cybersecurity developments matter disproportionately. Consumer retail contributes 37.6% and faces imported-cost, inflation and vehicle-duty pressures; the wider backdrop also includes elevated energy and transport costs.
Outlook
As at 17 August 2026, the next scheduled event is the filing for the quarter ending 30 September 2026, expected from 7 November 2026 and by 7 January 2027 based on exchange timing. That filing will be the next direct test of whether the cost and pricing measures reported on 7 August have stabilised operating earnings after the June slowdown.
The Kenya acquisition is the other important development to follow, although the available data cannot yet establish its return or contribution to group earnings. Lower domestic interest-rate expectations and a firmer rupee may ease parts of the financing and imported-cost environment, while energy-driven inflation remains a risk. The evidence therefore supports a balanced view: valuation and balance-sheet capacity are favourable, but the next filing must show that margin pressure is not becoming persistent.